{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:13:14Z","timestamp":1790957594833,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Global Medical Genetics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.gmg.2025.100056","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T11:37:09Z","timestamp":1746531429000},"page":"100056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical medication guidance for hypertension personalization through pharmacogenomic research and analysis"],"prefix":"10.1016","volume":"12","author":[{"given":"Qian","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoulei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yansong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"04","key":"10.1016\/j.gmg.2025.100056_bib1","first-page":"297","article-title":"Key points interpretation of the 'china cardiovascular health and disease report 2022\u2032","volume":"28","year":"2023","journal-title":"Chin. J. Cardiovasc. Med."},{"issue":"07","key":"10.1016\/j.gmg.2025.100056_bib2","first-page":"624","article-title":"Research progress of miRNA-29 in hypertensive kidney injury, Chinese","volume":"27","author":"Cong","year":"2019","journal-title":"J. Hypertens."},{"issue":"12","key":"10.1016\/j.gmg.2025.100056_bib3","first-page":"1111","article-title":"Can pharmacogenomics testing help in the treatment of hypertension? Chinese","volume":"27","author":"Guo","year":"2019","journal-title":"J. Hypertens."},{"key":"10.1016\/j.gmg.2025.100056_bib4","unstructured":"Expert Committee on Rational Use of Drugs of the National Health and Family Planning Commission, Guidelines for the Rational Medication Use of Hypertension (2nd Edition), Chinese Journal of Frontiers of Medicine Science. 9(07) (2017)28126."},{"key":"10.1016\/j.gmg.2025.100056_bib5","unstructured":"Chinese Society of Diabetes, The China Type Diabetes Prevention and Control Guidelines (2020 edition), CHINESE JOURNAL OF DIABETES MELLITUS. 13(04) (2021)315\u2013409."},{"issue":"2","key":"10.1016\/j.gmg.2025.100056_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann. Intern. Med."},{"issue":"09","key":"10.1016\/j.gmg.2025.100056_bib8","first-page":"815","article-title":"Research progress in pharmacogenomics of hypertension","volume":"29","author":"Wang","year":"2021","journal-title":"Chin. J. Hypertens."},{"issue":"1","key":"10.1016\/j.gmg.2025.100056_bib9","first-page":"52","article-title":"Research progress on the application of pharmacogenomics in the antihypertensive treatment with \u03b2-blockers","volume":"26","author":"Dai","year":"2016","journal-title":"YIXUE XINZHI ZHAZHI"},{"issue":"4","key":"10.1016\/j.gmg.2025.100056_bib10","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide distribution of cytochrome P450 alleles: a meta\u2010analysis of population\u2010scale sequencing projects","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.gmg.2025.100056_bib11","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s12272-018-1075-6","article-title":"CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes","volume":"41","author":"Byeon","year":"2018","journal-title":"Arch. pharmacal Res."},{"issue":"5","key":"10.1016\/j.gmg.2025.100056_bib12","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3109\/09540261.2013.825581","article-title":"Complexities of CYP2D6 gene analysis and interpretation","volume":"25","author":"Gaedigk","year":"2013","journal-title":"Int. Rev. Psychiatry"},{"issue":"10","key":"10.1016\/j.gmg.2025.100056_bib13","article-title":"Autoantibodies against the \u03b23-adrenoceptor protect from cardiac dysfunction in a rat model of pressure overload","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"issue":"03","key":"10.1016\/j.gmg.2025.100056_bib14","first-page":"325","article-title":"Polymorphisms of 7 drug-related genes for hypertension in 582 Han patients with hypertension","volume":"42","author":"Yu","year":"2021","journal-title":"Int. J. Lab. Med."},{"key":"10.1016\/j.gmg.2025.100056_bib15","unstructured":"Cui Haiying, Correlation analysis of plasma AngII and Apelin-13 factors with blood pressure levels in patients with diabetes mellitus and hypertension under spinal anesthesia, Shanxi Medical University. 2021."},{"issue":"3","key":"10.1016\/j.gmg.2025.100056_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00380-008-1101-6","article-title":"Insertion\/deletion polymorphism of angiotensin converting enzyme gene in Korean hypertensive adolescents","volume":"24","author":"Park","year":"2009","journal-title":"Heart Vessels"},{"issue":"06","key":"10.1016\/j.gmg.2025.100056_bib17","first-page":"712","article-title":"Distribution characteristics of genetic polymorphisms of sartan metabolizing enzyme CYP2C9 in hypertensive patients","volume":"13","author":"Wang","year":"2021","journal-title":"Chin. J. Evid. -Based Cardiovasc. Med."},{"issue":"17","key":"10.1016\/j.gmg.2025.100056_bib18","first-page":"1730","article-title":"Association between polymorphisms of antihypertensive drug-related genes and the incidence and antihypertensive effect of hypertension in Han population in Henan Province","volume":"41","author":"Sun","year":"2021","journal-title":"Chin. J. Hosp. Pharm."},{"key":"10.1016\/j.gmg.2025.100056_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cccn.2004.04.028","article-title":"CYP2C9 allele variants in Chinese hypertension patients and healthy controls","author":"Yu","year":"2004","journal-title":"Clin. Chim. Acta 348(1-2)"},{"issue":"3","key":"10.1016\/j.gmg.2025.100056_bib20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1072-7515(01)01163-2","article-title":"The frequency and effects of cytochrome P450(CYP)2C9 polymorphisms in patients receiving warfarin","volume":"194","author":"Tabrizi","year":"2002","journal-title":"J. Am. Coll. Surg."},{"issue":"6","key":"10.1016\/j.gmg.2025.100056_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00128071-200102060-00001","article-title":"Do women have more adverse drug reactions?","volume":"2","author":"Rademaker","year":"2001","journal-title":"Am. J. Clin. Dermatol."},{"issue":"1","key":"10.1016\/j.gmg.2025.100056_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2002.121216","article-title":"Pharmacokinetics of losartan and its metabolite E\u20103174 in relation to the CYP2C9 genotype","volume":"71","author":"Yasar","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"issue":"06","key":"10.1016\/j.gmg.2025.100056_bib23","first-page":"532","article-title":"Relationship between cytochrome P450 enzyme 2C9*3 and angiotensin II receptor type 1 (1166A>C) gene polymorphisms and the occurrence of essential hypertension and irbesartan antihypertensive efficacy, Chinese","volume":"28","author":"Dong","year":"2020","journal-title":"J. Hypertens."},{"issue":"06","key":"10.1016\/j.gmg.2025.100056_bib24","first-page":"559","article-title":"Distribution of polymorphisms of antihypertensive drug-related genes in the hypertensive population of Changsha Province, Journal of Clinical Cardiology","volume":"35","author":"Yang","year":"2019"},{"issue":"08","key":"10.1016\/j.gmg.2025.100056_bib25","first-page":"827","article-title":"Polymorphism distribution of hypertensive drug genes and individualized application of antihypertensive drugs in Anhui","volume":"42","author":"Deng","year":"2022","journal-title":"Chin. J. Hosp. Pharm."},{"issue":"06","key":"10.1016\/j.gmg.2025.100056_bib26","first-page":"471","article-title":"Distribution and detection of polymorphisms in antihypertensive drug-related genes in Han Chinese population","volume":"27","author":"Xu","year":"2011","journal-title":"Pharmaceuical J. Chin. People\u2019s Lib. Army"},{"key":"10.1016\/j.gmg.2025.100056_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12041-018-1053-2","article-title":"Association of polymorphisms of CYP11B2 gene-344C\/T and ACE gene I\/D with antihypertensive response to angiotensin receptor blockers in Chinese with hypertension","volume":"98","author":"Gong","year":"2019","journal-title":"J. Genet."},{"issue":"23","key":"10.1016\/j.gmg.2025.100056_bib28","first-page":"4017","article-title":"Polymorphisms of drug genes related to essential hypertension in Guizhou population","volume":"48","author":"Ren","year":"2019","journal-title":"CHONGQING Med. J."},{"issue":"23","key":"10.1016\/j.gmg.2025.100056_bib29","first-page":"3420","article-title":"Polymorphism analysis of antihypertensive drug-related genes in patients with essential hypertension in Chaozhou area","volume":"17","author":"Lin","year":"2020","journal-title":"Lab. Med. Clin."},{"issue":"4","key":"10.1016\/j.gmg.2025.100056_bib30","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI114844","article-title":"An insertion\/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels, The","volume":"86","author":"Rigat","year":"1990","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.gmg.2025.100056_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FPC.0b013e3283339bf3","article-title":"PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme","volume":"20","author":"Thorn","year":"2010","journal-title":"Pharm. Genom."},{"issue":"1","key":"10.1016\/j.gmg.2025.100056_bib32","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1038\/s41598-020-62362-8","article-title":"Defining individual-level genetic diversity and similarity profiles","volume":"10","author":"Zhanshan Sam Ma","year":"2020","journal-title":"Sci. Rep."},{"issue":"01","key":"10.1016\/j.gmg.2025.100056_bib33","first-page":"7","volume":"39","author":"Huang","year":"2005","journal-title":"Dongfeng, Et. al, Surv. Preval. Isol. systolic Hypertens. adults China, Chin. J. Prev. Med."},{"issue":"1","key":"10.1016\/j.gmg.2025.100056_bib34","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3390\/ijerph20010743","article-title":"Relationship between Built-Up Environment, Air Pollution, Activity Frequency and Prevalence of Hypertension-An Empirical Analysis from the Main City of Lanzhou","volume":"20","author":"Zhao","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"4","key":"10.1016\/j.gmg.2025.100056_bib35","first-page":"701","article-title":"Conceptualizing the socio-built environment: an expanded theoretical framework to promote a better understanding of risk for nonmedical opioid overdose outcomes in urban and non-urban settings, Journal of Urban Health","volume":"99","author":"Tempalski","year":"2022"}],"container-title":["Global Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2699940425000578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2699940425000578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:27:32Z","timestamp":1762644452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2699940425000578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2699940425000578"],"URL":"https:\/\/doi.org\/10.1016\/j.gmg.2025.100056","relation":{},"ISSN":["2699-9404"],"issn-type":[{"value":"2699-9404","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical medication guidance for hypertension personalization through pharmacogenomic research and analysis","name":"articletitle","label":"Article Title"},{"value":"Global Medical Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gmg.2025.100056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100056"}}